Implications of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline in a Modern Primary Prevention Multi-Ethnic Prospective Cohort (Multi-Ethnic Study of Atherosclerosis)

Charles Amir German, John W. McEvoy, Michael Blaha, Alain Bertoni, Michael D. Miedema, Gregory L. Burke, Joseph Yeboah

Research output: Contribution to journalArticle

Abstract

The American College of Physicians and the American Academy of Family Physician did not endorse the 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines citing multiple concerns. We assessed the increase in antihypertensive medication eligibility introduced by the 2017 hypertension guideline and the risk profile of those newly eligible for blood pressure medication using participants from the MultiEthnic Study of Atherosclerosis. The antihypertensive medication eligibility criteria of the Joint National Commission (JNC) VII, JNC VIII, and the 2017 ACC/AHA hypertension guidelines were applied to the cohort and the risk profile of those newly eligible was compared with those ineligible for antihypertensive medication under the 2017 ACC/AHA guidelines using Kaplan-Meier and Cox proportional hazard analysis. The new guideline increased antihypertensive medication eligibility by 46.8% and 96.7% compared with the JNC VII and JNC VIII guideline respectively. The newly eligible group did not have an increased risk of incident atherosclerotic cardiovascular disease, heart failure, or death compared with those ineligible (HR [95%CI]: 1.26 [0.96 to 1.65], p = 0.10; 0.75 [0.45 to 1.26], p = 0.27; 1.06 [−0.84 to 1.36], p = 0.62, respectively) after adjusting for age, gender, and race. The 2017 ACC/AHA hypertension guidelines extend antihypertensive medication to a substantial number of individuals although their risk profile appears to be similar to those previously ineligible.

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Primary Prevention
Atherosclerosis
Guidelines
Hypertension
Antihypertensive Agents
American Heart Association
Joints
Cardiology
Family Physicians
Cardiovascular Diseases
Heart Failure
Blood Pressure
Physicians

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Implications of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline in a Modern Primary Prevention Multi-Ethnic Prospective Cohort (Multi-Ethnic Study of Atherosclerosis). / German, Charles Amir; McEvoy, John W.; Blaha, Michael; Bertoni, Alain; Miedema, Michael D.; Burke, Gregory L.; Yeboah, Joseph.

In: American Journal of Cardiology, 01.01.2019.

Research output: Contribution to journalArticle

@article{3e9ba5c782874db0b19575c66d9c913b,
title = "Implications of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline in a Modern Primary Prevention Multi-Ethnic Prospective Cohort (Multi-Ethnic Study of Atherosclerosis)",
abstract = "The American College of Physicians and the American Academy of Family Physician did not endorse the 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines citing multiple concerns. We assessed the increase in antihypertensive medication eligibility introduced by the 2017 hypertension guideline and the risk profile of those newly eligible for blood pressure medication using participants from the MultiEthnic Study of Atherosclerosis. The antihypertensive medication eligibility criteria of the Joint National Commission (JNC) VII, JNC VIII, and the 2017 ACC/AHA hypertension guidelines were applied to the cohort and the risk profile of those newly eligible was compared with those ineligible for antihypertensive medication under the 2017 ACC/AHA guidelines using Kaplan-Meier and Cox proportional hazard analysis. The new guideline increased antihypertensive medication eligibility by 46.8{\%} and 96.7{\%} compared with the JNC VII and JNC VIII guideline respectively. The newly eligible group did not have an increased risk of incident atherosclerotic cardiovascular disease, heart failure, or death compared with those ineligible (HR [95{\%}CI]: 1.26 [0.96 to 1.65], p = 0.10; 0.75 [0.45 to 1.26], p = 0.27; 1.06 [−0.84 to 1.36], p = 0.62, respectively) after adjusting for age, gender, and race. The 2017 ACC/AHA hypertension guidelines extend antihypertensive medication to a substantial number of individuals although their risk profile appears to be similar to those previously ineligible.",
author = "German, {Charles Amir} and McEvoy, {John W.} and Michael Blaha and Alain Bertoni and Miedema, {Michael D.} and Burke, {Gregory L.} and Joseph Yeboah",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.amjcard.2018.12.040",
language = "English (US)",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Implications of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline in a Modern Primary Prevention Multi-Ethnic Prospective Cohort (Multi-Ethnic Study of Atherosclerosis)

AU - German, Charles Amir

AU - McEvoy, John W.

AU - Blaha, Michael

AU - Bertoni, Alain

AU - Miedema, Michael D.

AU - Burke, Gregory L.

AU - Yeboah, Joseph

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The American College of Physicians and the American Academy of Family Physician did not endorse the 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines citing multiple concerns. We assessed the increase in antihypertensive medication eligibility introduced by the 2017 hypertension guideline and the risk profile of those newly eligible for blood pressure medication using participants from the MultiEthnic Study of Atherosclerosis. The antihypertensive medication eligibility criteria of the Joint National Commission (JNC) VII, JNC VIII, and the 2017 ACC/AHA hypertension guidelines were applied to the cohort and the risk profile of those newly eligible was compared with those ineligible for antihypertensive medication under the 2017 ACC/AHA guidelines using Kaplan-Meier and Cox proportional hazard analysis. The new guideline increased antihypertensive medication eligibility by 46.8% and 96.7% compared with the JNC VII and JNC VIII guideline respectively. The newly eligible group did not have an increased risk of incident atherosclerotic cardiovascular disease, heart failure, or death compared with those ineligible (HR [95%CI]: 1.26 [0.96 to 1.65], p = 0.10; 0.75 [0.45 to 1.26], p = 0.27; 1.06 [−0.84 to 1.36], p = 0.62, respectively) after adjusting for age, gender, and race. The 2017 ACC/AHA hypertension guidelines extend antihypertensive medication to a substantial number of individuals although their risk profile appears to be similar to those previously ineligible.

AB - The American College of Physicians and the American Academy of Family Physician did not endorse the 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines citing multiple concerns. We assessed the increase in antihypertensive medication eligibility introduced by the 2017 hypertension guideline and the risk profile of those newly eligible for blood pressure medication using participants from the MultiEthnic Study of Atherosclerosis. The antihypertensive medication eligibility criteria of the Joint National Commission (JNC) VII, JNC VIII, and the 2017 ACC/AHA hypertension guidelines were applied to the cohort and the risk profile of those newly eligible was compared with those ineligible for antihypertensive medication under the 2017 ACC/AHA guidelines using Kaplan-Meier and Cox proportional hazard analysis. The new guideline increased antihypertensive medication eligibility by 46.8% and 96.7% compared with the JNC VII and JNC VIII guideline respectively. The newly eligible group did not have an increased risk of incident atherosclerotic cardiovascular disease, heart failure, or death compared with those ineligible (HR [95%CI]: 1.26 [0.96 to 1.65], p = 0.10; 0.75 [0.45 to 1.26], p = 0.27; 1.06 [−0.84 to 1.36], p = 0.62, respectively) after adjusting for age, gender, and race. The 2017 ACC/AHA hypertension guidelines extend antihypertensive medication to a substantial number of individuals although their risk profile appears to be similar to those previously ineligible.

UR - http://www.scopus.com/inward/record.url?scp=85059830226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059830226&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2018.12.040

DO - 10.1016/j.amjcard.2018.12.040

M3 - Article

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

ER -